NASDAQ:ACRS - Aclaris Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $38.00
  • Forecasted Upside: 126.73 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$16.76
▼ -0.04 (-0.24%)

This chart shows the closing price for ACRS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aclaris Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACRS

Analyst Price Target is $38.00
▲ +126.73% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Aclaris Therapeutics in the last 3 months. The average price target is $38.00, with a high forecast of $50.00 and a low forecast of $26.00. The average price target represents a 126.73% upside from the last price of $16.76.

This chart shows the closing price for ACRS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 contributing investment analysts is to buy stock in Aclaris Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/21/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/16/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2022

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/1/2022Cantor FitzgeraldReiterated RatingOverweightLow
5/11/2022William BlairReiterated RatingOutperformHigh
2/25/2022Cantor FitzgeraldReiterated RatingOverweightHigh
12/20/2021HC WainwrightReiterated RatingBuy$50.00High
12/9/2021SVB LeerinkReiterated RatingBuy$26.00Medium
11/15/2021HC WainwrightReiterated RatingBuy$49.00High
9/2/2021HC WainwrightReiterated RatingBuy$50.00High
8/9/2021HC WainwrightReiterated RatingBuyMedium
8/8/2021SVB LeerinkReiterated RatingBuy$26.00Medium
7/23/2021Jefferies Financial GroupInitiated CoverageBuy$32.00Low
6/15/2021Piper SandlerInitiated CoverageOverweightLow
4/21/2021HC WainwrightInitiated CoverageBuyLow
1/2/2020SVB LeerinkReiterated RatingOutperformLow
10/22/2019SVB LeerinkUpgradeMarket Perform ➝ OutperformHigh
10/11/2019William BlairReiterated RatingBuyLow
9/20/2019William BlairReiterated RatingBuyLow
9/6/2019JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
8/9/2019Cantor FitzgeraldReiterated RatingOverweight$24.00 ➝ $5.00High
6/27/2019SVB LeerinkDowngradeOutperform ➝ Market PerformHigh
6/12/2019Cantor FitzgeraldLower Price TargetOverweight$50.00 ➝ $24.00Low
5/6/2019SVB LeerinkInitiated CoverageOutperform$13.00High
3/22/2019Cantor FitzgeraldReiterated RatingBuy$50.00Low
3/15/2019Cantor FitzgeraldReiterated RatingBuy$50.00High
12/28/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
12/21/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
11/6/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
10/16/2018JMP SecuritiesLower Price TargetMarket Perform ➝ Buy$47.00 ➝ $34.00High
8/3/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
7/17/2018Cantor FitzgeraldReiterated RatingBuyLow
7/9/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
6/29/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
6/12/2018Cantor FitzgeraldSet Price TargetBuy$50.00Low
5/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
4/13/2018Cantor FitzgeraldReiterated RatingBuy$50.00Low
4/6/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
3/28/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$54.00 ➝ $52.00Low
3/19/2018Cantor FitzgeraldSet Price TargetBuy$50.00Medium
3/13/2018SVB LeerinkLower Price TargetOutperform ➝ Outperform$56.00 ➝ $54.00Low
3/12/2018Cantor FitzgeraldReiterated RatingBuy$50.00High
2/8/2018GuggenheimInitiated CoverageBuy ➝ Buy$53.00Medium
1/8/2018Cantor FitzgeraldSet Price TargetBuy$50.00High
12/15/2017Cantor FitzgeraldSet Price TargetBuy$50.00High
11/7/2017Cantor FitzgeraldReiterated RatingBuy$50.00N/A
10/4/2017Cantor FitzgeraldSet Price TargetBuy$50.00N/A
9/26/2017Cantor FitzgeraldReiterated RatingBuy$50.00Low
9/18/2017Cantor FitzgeraldReiterated RatingBuy$50.00Low
9/8/2017JMP SecuritiesReiterated RatingOutperform$39.00High
(Data available from 8/16/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/17/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/16/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/18/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/17/2022
  • 3 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
5/17/2022
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/16/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/16/2022
  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
8/15/2022

Current Sentiment

  • 1 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Aclaris Therapeutics logo
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
Read More

Today's Range

Now: $16.76
Low: $16.59
High: $17.08

50 Day Range

MA: $15.43
Low: $12.94
High: $18.00

52 Week Range

Now: $16.76
Low: $9.26
High: $19.97

Volume

421,770 shs

Average Volume

294,406 shs

Market Capitalization

$1.12 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6

Frequently Asked Questions

What sell-side analysts currently cover shares of Aclaris Therapeutics?

The following equities research analysts have issued reports on Aclaris Therapeutics in the last twelve months: Cantor Fitzgerald, HC Wainwright, StockNews.com, SVB Leerink LLC, and William Blair.
View the latest analyst ratings for ACRS.

What is the current price target for Aclaris Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Aclaris Therapeutics in the last year. Their average twelve-month price target is $38.00, suggesting a possible upside of 126.7%. HC Wainwright has the highest price target set, predicting ACRS will reach $50.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $26.00 for Aclaris Therapeutics in the next year.
View the latest price targets for ACRS.

What is the current consensus analyst rating for Aclaris Therapeutics?

Aclaris Therapeutics currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACRS will outperform the market and that investors should add to their positions of Aclaris Therapeutics.
View the latest ratings for ACRS.

What other companies compete with Aclaris Therapeutics?

How do I contact Aclaris Therapeutics' investor relations team?

Aclaris Therapeutics' physical mailing address is 640 LEE ROAD SUITE 200, WAYNE PA, 19087. The biotechnology company's listed phone number is (484) 324-7933 and its investor relations email address is [email protected] The official website for Aclaris Therapeutics is www.aclaristx.com. Learn More about contacing Aclaris Therapeutics investor relations.